- Trial phase
- Phase 3
- Time to market
- If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
- Why 7/10
- The single next hard, dated catalyst is the Phase 3 PROACT 1 topline data readout in Q2 2027 (~6-8 months away). This is a single-asset biotech and the readout is a make-or-break binary event for the stock, positive data would enable an accelerated-approval filing under the FDA's RMAT pathway, while negative data would likely render the company worthless. The impactScore of 7 reflects a high-concentration binary within ~6-12 months.
The next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.
Price Chart
Executive Summary
ProKidney (Nasdaq: PROK) is a late-clinical-stage cell therapy company developing REACT (rilparencel), a personalized autologous kidney-cell therapy for advanced chronic kidney disease (CKD) with type 2 diabetes. Positive Phase 2 data (July 2025) showed a 78% improvement in eGFR decline, and the FDA granted RMAT designation with an agreed accelerated-approval pathway using a single Phase 3 trial (PROACT 1). Enrollment for that trial completed in mid-2026, with topline data expected in Q2 2027. The stock trades at ~$1.41 with ~$182M cash funding operations into mid-2027. Analyst consensus is Buy with a mean $6.90 price target, but the stock is near its 52-week low, with high short interest (~13% of float) reflecting the binary nature of the Phase 3 readout. The KOL event on October 27, 2026 presents a near-term news event, but the defining catalyst remains the Phase 3 results over six months away.
How It Works
REACT is a personalized cell therapy made from the patient's own kidney cells. A small kidney biopsy is taken, the repair-oriented cells are multiplied in a lab, and then re-injected back into the patient's kidneys. These cells are thought to release regenerative signals that stabilize kidney function and slow disease progression. Because the cells come from the patient, no immune-suppressing drugs are needed.
Trial Status
The registrational Phase 3 PROACT 1 (REGEN-006) trial completed enrollment in mid-2026. It is evaluating bilateral injections of rilparencel in patients with Stage 3b/4 CKD and type 2 diabetes across over 70 clinical sites. Topline results are expected in Q2 2027. The Phase 2 REGEN-007 trial published positive results in the Clinical Journal of the American Society of Nephrology in January 2026. A second Phase 3 trial was halted as surplus to FDA approval requirements under the RMAT pathway.
The Two-Sided Case
Upcoming Catalysts
- Virtual KOL event on October 27, 2026, recapping mechanism-of-action data from ASN Kidney Week and providing a corporate update
- Q3 2026 earnings expected around November 9-10, 2026
- Phase 3 PROACT 1 topline data readout, Q2 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ProKidney Press Release PROK ·Originating report